{
  "id": 47,
  "query": "A large gene has dozens of exons, of which the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space. Each exon usually codes for one folded triple alpha helix. The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. Several missing exons are well tolerated by an organism. Which structure below is not involved in the proposed therapy?",
  "query_data": {
    "id": 47,
    "filename": "gpqa_cellbio_5_full.json",
    "question": "A large gene has dozens of exons, of which the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space. Each exon usually codes for one folded triple alpha helix. The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. Several missing exons are well tolerated by an organism. Which structure below is not involved in the proposed therapy?",
    "answer": "R-loops",
    "metadata": {
      "subject": "Life Science",
      "topic": "Cell Biology",
      "image_path": null,
      "tool_expected": [
        "analyze_dmd_mutation_therapy",
        "identify_non_involved_structures",
        "visualize_exon_skipping_mechanism",
        "query_rna_structure_involvement"
      ],
      "golden_answer": {
        "analyze_dmd_mutation_therapy": {
          "call": "analyze_dmd_mutation_therapy",
          "inputs": {
            "deleted_exons": [
              45,
              46,
              47,
              48,
              49,
              50
            ],
            "target_skip_exon": 51
          },
          "output": {
            "result": {
              "original_mutation": {
                "deleted_exons": [
                  45,
                  46,
                  47,
                  48,
                  49,
                  50
                ],
                "total_deleted_bases": 990,
                "frame_shift": 0,
                "in_frame": true,
                "out_of_frame": false
              },
              "therapy_outcome": {
                "deleted_exons": [
                  45,
                  46,
                  47,
                  48,
                  49,
                  50,
                  51
                ],
                "total_deleted_bases": 1140,
                "frame_shift": 0,
                "in_frame": true,
                "out_of_frame": false
              },
              "morpholino_binding": {
                "target_exon": 51,
                "morpholino_length": 25,
                "binding_efficiency_percent": 92.5,
                "expected_skipping": true
              },
              "therapy_success": false
            },
            "metadata": {
              "analysis_type": "comprehensive_dmd_therapy",
              "components": [
                "frame_shift",
                "exon_skipping",
                "morpholino_binding"
              ]
            }
          }
        },
        "identify_non_involved_structures": {
          "call": "identify_non_involved_structures",
          "inputs": {},
          "output": {
            "result": {
              "non_involved_structures": [
                {
                  "name": "R_loops",
                  "function": "RNA-DNA hybrid structures",
                  "description": "Formed during transcription, not splicing"
                }
              ],
              "count": 1
            },
            "metadata": {
              "query_type": "exclusion_filter"
            }
          }
        },
        "visualize_exon_skipping_mechanism": {
          "call": "visualize_exon_skipping_mechanism",
          "inputs": {
            "deleted_exons": [
              45,
              46,
              47,
              48,
              49,
              50
            ],
            "target_exon": 51
          },
          "output": {
            "result": "./tool_images/exon_skipping_mechanism.png",
            "metadata": {
              "file_type": "PNG",
              "size": 123498,
              "visualization_type": "exon_structure_comparison"
            }
          }
        },
        "query_rna_structure_involvement": {
          "call": "query_rna_structure_involvement",
          "inputs": {
            "structure_name": "R_loops"
          },
          "output": {
            "result": {
              "structure_name": "R_loops",
              "function": "RNA-DNA hybrid structures",
              "involved_in_therapy": false,
              "description": "Formed during transcription, not splicing"
            },
            "metadata": {
              "database_query": true,
              "found": true
            }
          }
        }
      },
      "original_question_id": "5",
      "_dataset_filename": "refine_merged_single_questions.json"
    },
    "usage_tool_protocol": [
      {
        "type": "function",
        "function": {
          "name": "query_rna_structure_involvement",
          "description": "查询RNA结构在Morpholino治疗中的参与情况",
          "strict": true,
          "parameters": {
            "type": "object",
            "properties": {
              "structure_name": {
                "type": "string",
                "description": "RNA结构名称"
              }
            },
            "required": [
              "structure_name"
            ]
          }
        },
        "additionalProperties": {
          "function_path": "./tools/molecular_biology_toolkit_claude_5.py",
          "resolved_file_path": "toolkits/life_science/cell_biology/molecular_biology_toolkit_claude_5.py",
          "resolved_dir": "toolkits/life_science/cell_biology"
        }
      },
      {
        "type": "function",
        "function": {
          "name": "analyze_dmd_mutation_therapy",
          "description": "分析DMD突变和外显子跳跃治疗策略",
          "strict": true,
          "parameters": {
            "type": "object",
            "properties": {
              "deleted_exons": {
                "type": "array",
                "items": {
                  "type": "integer"
                },
                "description": "缺失的外显子编号列表"
              },
              "target_skip_exon": {
                "type": "integer",
                "description": "目标跳跃的外显子编号"
              }
            },
            "required": [
              "deleted_exons",
              "target_skip_exon"
            ]
          }
        },
        "additionalProperties": {
          "function_path": "./tools/molecular_biology_toolkit_claude_5.py"
        }
      },
      {
        "type": "function",
        "function": {
          "name": "identify_non_involved_structures",
          "description": "结合数据库识别不参与Morpholino治疗的RNA结构",
          "strict": true,
          "parameters": {
            "type": "object",
            "properties": {},
            "required": []
          }
        },
        "additionalProperties": {
          "function_path": "./tools/molecular_biology_toolkit_claude_5.py"
        }
      },
      {
        "type": "function",
        "function": {
          "name": "visualize_exon_skipping_mechanism",
          "description": "可视化外显子跳跃机制",
          "strict": true,
          "parameters": {
            "type": "object",
            "properties": {
              "deleted_exons": {
                "type": "array",
                "items": {
                  "type": "integer"
                },
                "description": "缺失的外显子编号列表"
              },
              "target_exon": {
                "type": "integer",
                "description": "目标外显子编号"
              }
            },
            "required": [
              "deleted_exons",
              "target_exon"
            ]
          }
        },
        "additionalProperties": {
          "function_path": "./tools/molecular_biology_toolkit_claude_5.py"
        }
      }
    ],
    "augmented_versions": [
      {
        "augmented_question": "一条大型结构蛋白基因（中央外显子各编码一个折叠的三股α螺旋重复结构，用于连接肌膜/细胞骨架/细胞外空间）可耐受多个中央外显子缺失。为矫正阅读框，拟用Morpholino（25 nt）靶向目标外显子5'端的pre-mRNA，阻断剪接体结合以诱导外显子跳跃。现给出两个临床情景及工具返回结果，请完成多项判定，并最终指出“哪一结构不参与该治疗”。\n\n已知工具结果（均来自给定执行记录）：\n- 通用：Morpholino长度=25 nt；两情景的绑定效率=92.5%，均“expected_skipping=true”。\n- 情景A（患者A）：已缺失外显子[45,46]，original total_deleted_bases=330，original in_frame=true；拟再跳跃外显子47后，therapy total_deleted_bases=480，therapy in_frame=true；可视化图（机制图ID=mech_A）路径=./tool_images/exon_skipping_mechanism.png（来源于步骤5）。\n- 情景B（患者B）：已缺失外显子[48,49,50]，original total_deleted_bases=450，original in_frame=true；拟再跳跃外显子51后，therapy total_deleted_bases=600，therapy in_frame=true；可视化图（机制图ID=mech_B）路径=./tool_images/exon_skipping_mechanism.png（来源于步骤8）。\n- 结构参与检索：尝试查询spliceosome_U1_U2_5prime_splice_site、ribosome_80S_translation_complex以及ESE_SRSF_family_sites_exon47_5prime的数据库均返回“unable to open database file”（步骤2、3、6）。\n\n任务：\n1) 分别计算情景A与B在“原突变”和“跳跃后”的mod3_shift（即total_deleted_bases mod 3），并给出frame_restored（跳跃后阅读框是否被恢复；若原本即为in-frame，则视为保持/仍为true）。\n2) 分别给出两情景的predicted_junction（跳跃后直接相邻拼接的外显子对）。假设：\n   - 情景A：若跳过47，则拼接为exon44–exon48。\n   - 情景B：若跳过51，则拼接为exon47–exon52。\n3) 说明上述拼接是否保持蛋白折叠重复域连续性。给定规则：每个外显子≈1条α螺旋，三条为一组折叠单元；跨越的缺失外显子数若为3的倍数，则认为“连续性保持”，否则视为“可能破坏相位”。\n4) 情景A需报告ESE_overlap_risk并给出建议的Morpholino覆盖窗口。近似法则（为可计算而给定）：若覆盖窗口相对目标外显子起始位点E+1定义为[E−x..E+y]且总长度=25 nt，则ESE_overlap_risk=窗口内处于外显子侧的碱基数/25。目标：在阻断5'端受体位点的同时尽量降低该风险。\n5) 比较两情景的off_target_risk。已知两者长度与绑定效率相同，若无序列差异信息，则将二者判为“相当”。基于工具结果中therapy_success=false（步骤4、7），给出“较优方案”的选择理由。\n6) 在以下四个结构中，判定哪一个“不参与所提的治疗机制”（即Morpholino介导的前体mRNA剪接调控），并给出论证，需引用：\n   - 步骤1/9与步骤3的数据库检索状况（均报错）；\n   - 本题第3步与“验证矩阵”的机制证据。\n   四个候选结构：\n   a) pre-mRNA目标外显子5'端剪接位点（受体/供体边界）\n   b) spliceosome_U1_U2_5prime_splice_site（剪接体U1/U2相关识别）\n   c) ESE_SRSF_family_sites_exon47_5prime（外显子增强子/SR蛋白位点）\n   d) ribosome_80S_translation_complex（翻译复合体）\n\n请给出：\n- 情景A与B的frame_restored与mod3_shift结果；\n- 两情景的predicted_junction与机制图ID，并说明折叠重复域连续性；\n- 情景A的ESE_overlap_risk与推荐覆盖窗口；\n- 两情景off_target_risk的比较与较优方案；\n- 指明并论证“不参与的结构”；\n- 提交最终验证矩阵：对上述四个结构给出参与度分数（0~1）与理由，确保跨情景一致、可复核。",
        "final_answer": {
          "non_involved_structure": {
            "name": "ribosome_80S_translation_complex",
            "reason": "Morpholino在前体mRNA剪接阶段起效，阻断U1/U2对剪接位点的识别并调制ESE/ESS依赖的外显子选择；核糖体80S属于翻译阶段装置，不直接参与剪接调控。步骤3对核糖体的数据库查询失败（unable to open database file），但不影响基于机制与验证矩阵的判定。"
          },
          "scenarios": {
            "A": {
              "initial_deleted_exons": [
                45,
                46
              ],
              "initial_total_deleted_bases": 330,
              "initial_mod3_shift": 0,
              "initial_in_frame": true,
              "after_skip_target_exon": 47,
              "after_total_deleted_bases": 480,
              "after_mod3_shift": 0,
              "frame_restored": true,
              "predicted_junction": "exon44–exon48",
              "mechanism_fig_id": "mech_A",
              "repeat_domain_continuity": true,
              "continuity_reason": "跨越缺失外显子数=3（45,46,47），为3的倍数，三股螺旋折叠单元相位保持。",
              "morpholino_design": {
                "recommended_window": "E−15..E+9 (相对外显子47起始位点E+1)",
                "window_intronic_bases": 16,
                "window_exonic_bases": 9,
                "ESE_overlap_risk": 0.36,
                "note": "将覆盖更多放置在内含子侧以避开外显子内的ESE/ESS；仍跨越边界以有效阻断剪接体装配。"
              },
              "binding_efficiency_percent": 92.5,
              "therapy_success_flag_from_tool": false
            },
            "B": {
              "initial_deleted_exons": [
                48,
                49,
                50
              ],
              "initial_total_deleted_bases": 450,
              "initial_mod3_shift": 0,
              "initial_in_frame": true,
              "after_skip_target_exon": 51,
              "after_total_deleted_bases": 600,
              "after_mod3_shift": 0,
              "frame_restored": true,
              "predicted_junction": "exon47–exon52",
              "mechanism_fig_id": "mech_B",
              "repeat_domain_continuity": false,
              "continuity_reason": "跨越缺失外显子数=4（48,49,50,51），非3的倍数，三股螺旋折叠单元可能发生相位错配。",
              "binding_efficiency_percent": 92.5,
              "therapy_success_flag_from_tool": false
            }
          },
          "off_target_risk_comparison": {
            "A": "low (approximately equal to B given same length and binding efficiency, no sequence provided)",
            "B": "low (approximately equal to A)",
            "preferred_plan": "no_additional_exon_skipping",
            "justification": "两情景在跳跃前已为in-frame（mod3=0），工具亦标注therapy_success=false。额外给药仅增加潜在脱靶与ESE扰动风险而无阅读框获益，故优选不追加跳跃。若必须二选一，A在折叠域连续性评估更优。"
          },
          "validation_matrix": [
            {
              "structure": "pre-mRNA 5' splice site of target exon (边界位点)",
              "participation_score": 1.0,
              "evidence": "Morpholino需跨越目标外显子5'端边界阻断剪接体装配；两情景共同机制（题干+设计窗口）。"
            },
            {
              "structure": "spliceosome_U1_U2_5prime_splice_site",
              "participation_score": 1.0,
              "evidence": "治疗通过阻断U1/U2对5'端/受体-供体位点的结合实现外显子跳跃；步骤2数据库查询失败但不影响机制判定。"
            },
            {
              "structure": "ESE_SRSF_family_sites_exon47_5prime",
              "participation_score": 0.7,
              "evidence": "ESE/ESS调控外显子选择；情景A专门评估并通过将窗口偏向内含子侧降低ESE_overlap_risk=0.36；步骤6数据库查询失败但风险评估在题设近似法下可计算。"
            },
            {
              "structure": "ribosome_80S_translation_complex",
              "participation_score": 0.0,
              "evidence": "核糖体参与翻译非剪接；步骤3数据库查询失败，且本题各机制环节均在前体mRNA剪接阶段完成。"
            }
          ]
        },
        "solution_outline": [
          "读取工具提供的total_deleted_bases，分别对原突变与跳跃后取mod 3，即得mod3_shift；若结果为0则为in-frame。",
          "由题设假设给出predicted_junction：情景A为exon44–exon48，情景B为exon47–exon52；对应机制图ID分别为mech_A、mech_B（均指向给定PNG路径）。",
          "按给定规则判断折叠重复域连续性：跨越的缺失外显子数为3的倍数→连续性保持；否则可能破坏相位。",
          "计算情景A的ESE_overlap_risk：选择一个25 nt覆盖窗口[E−x..E+y]尽量把更多碱基放在内含子侧以降低外显子内重叠比例；用外显子侧碱基数/25得到风险值。",
          "off_target_risk比较：两者长度与绑定效率相同且无序列差异信息→判为相当；结合工具therapy_success=false，给出更倾向的“无需额外跳跃”的方案。",
          "结构参与判定：Morpholino作用于pre-mRNA剪接阶段，涉及剪接位点、U1/U2、ESE/SR；与翻译阶段的80S核糖体无直接参与。引用步骤2/3/6报错的事实（数据库不可用）并以机制推断佐证；在验证矩阵中量化参与度分数以形成一致结论。"
        ],
        "verification": "1) mod3核验：情景A 330 mod 3=0，480 mod 3=0；情景B 450 mod 3=0，600 mod 3=0，均与工具给定in_frame=true一致。2) 拼接位点：按题设假设，A跳过47后为exon44–exon48；B跳过51后为exon47–exon52；机制图ID分别mech_A与mech_B，对应给定PNG路径（步骤5、8）。3) 折叠域连续性：A跨越3个外显子（倍数为3）→保持；B跨越4个外显子（非3的倍数）→可能破坏。4) ESE_overlap_risk复算：窗口E−15..E+9总长25 nt，其中外显子侧9 nt→9/25=0.36。5) off_target_risk比较：长度与绑定效率相同（92.5%），且无序列差异输入→判定A≈B；结合工具therapy_success=false（步骤4、7）→优选不追加跳跃。6) 不参与结构核验：根据治疗发生于剪接阶段且验证矩阵给予核糖体参与度=0.0，可与机制常识交叉确认“ribosome_80S_translation_complex”为不参与项。"
      }
    ],
    "refined_versions": [
      {
        "refined_question": "背景：拟以25 nt Morpholino靶向目标外显子5'端pre-mRNA以诱导外显子跳跃，纠正阅读框。两情景的寡核苷酸长度相同、结合效率相同，均可诱导外显子跳跃；两情景的治疗尝试未达预期（therapy_success=false）。相关数据库（U1/U2 5' splice site、80S翻译复合体、ESE于外显子47近5'端）检索均未返回可用记录（报错）。\n已知：\n- 情景A（患者A）：已缺失外显子[45,46]；original total_deleted_bases=330，original in_frame=true；如再跳跃外显子47，则therapy total_deleted_bases=480，therapy in_frame=true。跳跃后拼接假设：exon44–exon48；机制图ID=mech_A。\n- 情景B（患者B）：已缺失外显子[48,49,50]；original total_deleted_bases=450，original in_frame=true；如再跳跃外显子51，则therapy total_deleted_bases=600，therapy in_frame=true。跳跃后拼接假设：exon47–exon52；机制图ID=mech_B。\n- 折叠重复域连续性判定规则：每个外显子≈1条α螺旋，三条为一组；跨越的缺失外显子数为3的倍数→“连续性保持”，否则→“可能破坏相位”。\n- 情景A设计需评估ESE_overlap_risk。定义：覆盖窗口相对目标外显子起始位点E+1为[E−x..E+y]且总长度=25 nt，ESE_overlap_risk=窗口内位于外显子侧的碱基数/25；目标是在阻断5'端剪接位点的同时尽量降低该风险。\n任务：\n1) 分别给出情景A与B在“原突变”和“跳跃后”的mod3_shift（total_deleted_bases mod 3），并给出frame_restored（若原本即为in-frame，则视为保持true）。\n2) 分别给出两情景的predicted_junction与机制图ID。\n3) 依据给定规则，判断上述拼接是否保持折叠重复域连续性。\n4) 情景A报告ESE_overlap_risk，并给出推荐的Morpholino覆盖窗口表达形式（长度=25 nt），使其跨越外显子—内含子边界且尽量降低ESE_overlap_risk。\n5) 比较两情景的off_target_risk（在长度与结合效率相同、无序列差异信息时判为相当），并在therapy_success=false前提下给出较优方案与理由。\n6) 在以下四个结构中判定哪一个不参与该治疗机制（Morpholino介导的前体mRNA剪接调控），并给出论证，需引用“数据库检索均未返回记录（报错）”与本题第(3)步及“验证矩阵”的机制证据；同时提交验证矩阵：对下列四个结构给出参与度分数（0~1）与简要理由（跨情景一致）：\n   a) pre-mRNA目标外显子5'端剪接位点（受体/供体边界）\n   b) spliceosome_U1_U2_5prime_splice_site\n   c) ESE_SRSF_family_sites_exon47_5prime\n   d) ribosome_80S_translation_complex\n说明：核酸长度以nt计；除(6)中的参与度分数外，其余结果以符号表达式给出。",
        "final_answer": {
          "(1)": {
            "A": {
              "mod3_shift_original": "330 mod 3",
              "mod3_shift_therapy": "480 mod 3",
              "frame_restored": "true"
            },
            "B": {
              "mod3_shift_original": "450 mod 3",
              "mod3_shift_therapy": "600 mod 3",
              "frame_restored": "true"
            }
          },
          "(2)": {
            "A": {
              "predicted_junction": "exon44–exon48",
              "mechanism_fig_id": "mech_A"
            },
            "B": {
              "predicted_junction": "exon47–exon52",
              "mechanism_fig_id": "mech_B"
            }
          },
          "(3)": {
            "A_repeat_domain_continuity": "保持（跨越缺失外显子数为3的倍数）",
            "B_repeat_domain_continuity": "可能破坏（跨越缺失外显子数非3的倍数）"
          },
          "(4)": {
            "ESE_overlap_risk_A": "m/25（m为窗口内位于外显子侧的碱基数）",
            "recommended_window_A": "[E−(25−m)..E+(m−1)]，取m为满足跨越边界且可阻断剪接位点的最小值（m≥1）以最小化m/25"
          },
          "(5)": {
            "off_target_risk_A_vs_B": "相当（长度与结合效率相同，且无序列差异信息）",
            "preferred_plan": "不追加外显子跳跃",
            "justification": "在therapy_success=false且两情景原本均为in-frame的前提下，继续跳跃不改善阅读框且增加潜在风险；若必须二选一，选A因折叠重复域连续性判断更优"
          },
          "(6)": {
            "non_involved_structure": "ribosome_80S_translation_complex",
            "reason": "该机制发生于前体mRNA剪接阶段；数据库检索对相关条目未返回记录（报错）不影响基于机制的判定；第(3)步与验证矩阵均指向剪接层面证据，翻译复合体不参与",
            "validation_matrix": [
              {
                "structure": "pre-mRNA目标外显子5'端剪接位点",
                "participation_score": 1.0,
                "rationale": "需跨越外显子—内含子边界以阻断装配，跨情景一致"
              },
              {
                "structure": "spliceosome_U1_U2_5prime_splice_site",
                "participation_score": 1.0,
                "rationale": "作用机理为干扰U1/U2相关识别实现外显子跳跃；尽管数据库检索报错，机制证据充分"
              },
              {
                "structure": "ESE_SRSF_family_sites_exon47_5prime",
                "participation_score": 0.7,
                "rationale": "ESE影响外显子选择；(4)中通过最小化m降低ESE_overlap_risk，提示其为需权衡的参与因子"
              },
              {
                "structure": "ribosome_80S_translation_complex",
                "participation_score": 0.0,
                "rationale": "翻译阶段结构，不参与前体mRNA剪接调控；数据库检索报错且无机制需求"
              }
            ]
          }
        }
      }
    ],
    "metadata_summary": {
      "subject": "Life Science",
      "topic": "Cell Biology",
      "original_question_id": "5",
      "subject_topic_key": "Life Science::Cell Biology"
    }
  },
  "model": "glm-4.6v",
  "use_tools": true,
  "mode": "tool_mode",
  "rounds": 1,
  "messages": [
    {
      "role": "system",
      "content": "你是一个顶尖的 AI 科学助手，你的任务是解决来自物理、化学、生物等领域的复杂、多模态、多步骤问题。\n\n# 任务指令：两阶段方法\n\n你必须严格遵循以下两个阶段来回答问题：\n\n**阶段 1: 规划 (Planning)**\n在开始执行任何操作之前，你必须首先生成一个高阶的、分步骤的“计划”。这个计划应该概述你打算如何分解问题、使用哪些工具、以及工具之间的依赖关系。\n\n**阶段 2: 执行 (Execution)**\n在提交计划后，你将开始逐一执行。你必须严格遵循以下的 \"ReAct\" 格式 (Thought, Action, Observation)，直到你得出最终答案。\n\n---\n\n**输出格式规范**\n\n**[阶段 1: 规划]**\nPlan:\n\n1. [你的计划步骤 1，例如：分析输入图像中的分子结构]\n2. [你的计划步骤 2，例如：使用 `analyze_molecule` 工具获取 SMILES]\n3. [你的计划步骤 3，例如：将 SMILES 传入 `calculate_properties` 工具]\n4. ...\n5. [你的计划步骤 N，例如：总结所有属性并回答问题]\n\n**[阶段 2: 执行]**\nThought: [描述你当前的思考，你正处于计划的第几步，以及你为什么需要调用这个特定的工具。]\nAction: 请你在这一步发出工具调用\n\n[在你提交 Action 后，你将收到一个 Observation]\n\nObservation: [这里将由评测系统插入工具的返回结果]\n\n[然后你重复这个循环]\n\nThought: [基于上一步的 Observation，你的新思考。]\nAction: 请你在这一步发出工具调用\n\n...\n[当你收集到所有信息并准备好回答时]\n\nThought: [我已收集到所有必要信息，现在可以生成最终答案了。]\nFinal Answer: [这里是对原始问题的最终、完整回答。]"
    },
    {
      "role": "user",
      "content": "A large gene has dozens of exons, of which the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space. Each exon usually codes for one folded triple alpha helix. The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. Several missing exons are well tolerated by an organism. Which structure below is not involved in the proposed therapy?\nYou should strictly respond in this exact format and answer the question in its original language:\n###Answer###\n{The final answer wrapped in LaTeX boxed format $\\boxed{}$}"
    },
    {
      "role": "assistant",
      "content": "\n###Answer###\n$\\boxed{\\text{DNA}}$"
    }
  ],
  "metadata": {
    "subject": "Life Science",
    "topic": "Cell Biology",
    "image_path": null,
    "tool_expected": [
      "analyze_dmd_mutation_therapy",
      "identify_non_involved_structures",
      "visualize_exon_skipping_mechanism",
      "query_rna_structure_involvement"
    ],
    "golden_answer": {
      "analyze_dmd_mutation_therapy": {
        "call": "analyze_dmd_mutation_therapy",
        "inputs": {
          "deleted_exons": [
            45,
            46,
            47,
            48,
            49,
            50
          ],
          "target_skip_exon": 51
        },
        "output": {
          "result": {
            "original_mutation": {
              "deleted_exons": [
                45,
                46,
                47,
                48,
                49,
                50
              ],
              "total_deleted_bases": 990,
              "frame_shift": 0,
              "in_frame": true,
              "out_of_frame": false
            },
            "therapy_outcome": {
              "deleted_exons": [
                45,
                46,
                47,
                48,
                49,
                50,
                51
              ],
              "total_deleted_bases": 1140,
              "frame_shift": 0,
              "in_frame": true,
              "out_of_frame": false
            },
            "morpholino_binding": {
              "target_exon": 51,
              "morpholino_length": 25,
              "binding_efficiency_percent": 92.5,
              "expected_skipping": true
            },
            "therapy_success": false
          },
          "metadata": {
            "analysis_type": "comprehensive_dmd_therapy",
            "components": [
              "frame_shift",
              "exon_skipping",
              "morpholino_binding"
            ]
          }
        }
      },
      "identify_non_involved_structures": {
        "call": "identify_non_involved_structures",
        "inputs": {},
        "output": {
          "result": {
            "non_involved_structures": [
              {
                "name": "R_loops",
                "function": "RNA-DNA hybrid structures",
                "description": "Formed during transcription, not splicing"
              }
            ],
            "count": 1
          },
          "metadata": {
            "query_type": "exclusion_filter"
          }
        }
      },
      "visualize_exon_skipping_mechanism": {
        "call": "visualize_exon_skipping_mechanism",
        "inputs": {
          "deleted_exons": [
            45,
            46,
            47,
            48,
            49,
            50
          ],
          "target_exon": 51
        },
        "output": {
          "result": "./tool_images/exon_skipping_mechanism.png",
          "metadata": {
            "file_type": "PNG",
            "size": 123498,
            "visualization_type": "exon_structure_comparison"
          }
        }
      },
      "query_rna_structure_involvement": {
        "call": "query_rna_structure_involvement",
        "inputs": {
          "structure_name": "R_loops"
        },
        "output": {
          "result": {
            "structure_name": "R_loops",
            "function": "RNA-DNA hybrid structures",
            "involved_in_therapy": false,
            "description": "Formed during transcription, not splicing"
          },
          "metadata": {
            "database_query": true,
            "found": true
          }
        }
      }
    },
    "original_question_id": "5",
    "_dataset_filename": "refine_merged_single_questions.json"
  },
  "metadata_summary": {
    "subject": "Life Science",
    "topic": "Cell Biology",
    "original_question_id": "5",
    "subject_topic_key": "Life Science::Cell Biology"
  },
  "expected_format": "free_text",
  "model_raw_answer": "\n###Answer###\n$\\boxed{\\text{DNA}}$",
  "model_last_assistant_message": {
    "role": "assistant",
    "content": "\n###Answer###\n$\\boxed{\\text{DNA}}$"
  },
  "mode_folder": "with_tools_react"
}